Côd QR

A Randomized Phase 2 Trial of Nivolumab Versus Nivolumab-Ipilimumab Combination in EGFR-Mutant NSCLC

Introduction: Although immune checkpoint inhibitors (ICIs) have dramatically improved outcomes for nononcogene-addicted NSCLC, monotherapy with programmed cell death protein-1 (PD1) inhibition has been associated with low efficacy in the EGFR-mutant setting. Given the potential for synergism with co...

Disgrifiad llawn

Wedi'i Gadw mewn:
Prif Awduron: Gillianne G.Y. Lai, MBBS, Jia Chi Yeo, PhD, Amit Jain, MBBS, PhD, Siqin Zhou, MSc, Mengyuan Pang, MSc, Jacob J.S. Alvarez, BSc, Ngak Leng Sim, BCS, Aaron C. Tan, MBBS, FRACP, PhD, Lisda Suteja, BSc, Tze Wei Lim, BSc, Yu Amanda Guo, PhD, Meixin Shen, PhD, Stephanie P.L. Saw, MBBS, Neha Rohatgi, BSc, Joe P.S. Yeong, MBBS, PhD, Angela Takano, MBBS, Kiat Hon Lim, MBBS, Apoorva Gogna, MBBS, Chow Wei Too, MBBS, Kun Da Zhuang, MBBS, Wan Ling Tan, MBBS, Ravindran Kanesvaran, MBBS, Quan Sing Ng, MBBS, Mei Kim Ang, MBBS, Tanujaa Rajasekaran, MBBS, Lanying Wang, MBBS, Chee Keong Toh, MBBS, Wan-Teck Lim, MBBS, Wai Leong Tam, PhD, Sze Huey Tan, PhD, Anders M.J. Skanderup, PhD, Eng-Huat Tan, MBBS, Daniel S.W. Tan, BSc, MBBS, MRCP, PhD
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Elsevier 2022-12-01
Cyfres:JTO Clinical and Research Reports
Pynciau:
Lung cancer
Epidermal growth factor receptor
Immunotherapy
Biomarkers
Mynediad Ar-lein:http://www.sciencedirect.com/science/article/pii/S2666364322001400
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg